We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Ondine Biomedical Inc. | OBI | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.125 | 1.89% | 6.75 | 10:41:32 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 6.625 | 6.625 | 6.75 | 6.75 | 6.625 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 04/4/2024 08:30 by jailbird No denying all that As an investor, I only care about the balance sheet, potential revenues, profits and the share price |
Posted at 25/3/2024 11:44 by luzley A 20p share offer at this stage is fair and realistic. In another 12 months this will be worth significantly more. I'm happy to wait and accumulate but if offers appear, given previous investor support, I'm also interested. |
Posted at 21/3/2024 16:03 by luzley Ondine has specifically addressed any need for funding in its last interim. This was prior to the investor-led financing at 9p - a premium to the shareprice at the time. The CEO quotes:The rise of antimicrobial resistance ("AMR") is driving governments and research institutes to seek new solutions to combat antimicrobial-resist |
Posted at 20/3/2024 09:23 by z1co My posts must have upset JB on the other thread.JB is a very cautious investor , it took him ages to actually buy the shares and now he thinks the FDA are also like him and will take ages to get the product approved. Hey fellow not everyone is as slow as you. |
Posted at 20/3/2024 09:04 by jailbird FDA phase 3 SHOULD get approved, but there is no certainty of approval and timescalesI have seen FDA prolong trials, it is not always as straight forward as some investors think. A bit naïve and over confident to assume that. |
Posted at 16/1/2024 18:08 by z1co Indeed marvelman , the product which is already approved in Canada , The EU , UK and Mexico has huge potential worldwide.They will start Phase 3 trials in the US this year and these trials will be for 5 to 6 months of duration. We will see more investors start to buy when they start these phase 3 trials and many more upon approval. Like with most big gains ( multi bags ) patience is also required. |
Posted at 16/1/2024 16:48 by marvelman Nice start to 2024 with so much more ahead over the coming weeks and months. Its certain that this high flyer guy sees more in the company than those wavering investors who are still sitting on the sidelines. |
Posted at 08/1/2024 21:19 by jailbird So rude,No need to take it out on me if you losing your life savings. My new year resolution for you Try to listen, learn and engage respectfully with experienced/other investors |
Posted at 05/12/2023 11:52 by bamboo2 5 December 2023Ondine Biomedical Inc. ("OBI", "Ondine", or the "Company") Result of Placing and Subscription Broker Option to raise up to GBP1.25 million Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company, is pleased to confirm, further to the announcement made on 30 November 2023, (the "Launch Announcement"), the successful completion of the Placing and Subscription at the Issue Price of 9 pence per New Common Share. The Issue Price represents a premium of approximately 9 per cent. to the closing mid-price of the Common Shares on 29 November 2023. The total gross proceeds of the Placing and the Subscription to date stand at approximately GBP2.75 million (C$4.74 million). The Placing has conditionally raised aggregate gross proceeds of approximately GBP2.03 million (C$3.50 million) pursuant to the placing of 22,554,435 Placing Shares with new and existing investors. The Subscription has raised further gross proceeds of approximately GBP0.72 million (C$1.24 million) pursuant to subscriptions received for 8,001,118 Subscription Shares, excluding any further subscriptions by employees (the "Employee Subscription"). The 30,555,553 New Common Shares in aggregate to be issued pursuant to the Placing and the Subscription represent approximately 15.7 per cent. of the existing issued share capital of the Company. All shares issued pursuant to the Placing and Subscription will be issued non pre-emptively under the Company's existing authorities, and are expected to be admitted to trading on AIM on or around 8 December 2023. Singer Capital Markets Securities Limited ("SCM") and RBC Europe Limited ("RBC") acted as Joint Bookrunners for the Placing. The Placing was conducted following a market sounding by way of an accelerated book build process. Further to the announcement on 4 December 2023, a Broker Option to raise up to GBP1.25 million (C$2.15 million) will remain open until 4.45pm on 8 December 2023, in order to satisfy potential further demand from institutional investors and other Relevant Persons. If the Broker Option is exercised in whole or in part, further announcements will be made as appropriate. Any further issuance of New Common Shares following any exercise of the Broker Option will be made on a non pre-emptive basis. Similarly, any further issuance pursuant to the Employee Subscription will be confirmed by way of a further announcement on or before 8 December 2023 and will be made on a non pre-emptive basis. The Employee Subscription will remain open until further notice, but will close in any event by 4.45 p.m. on 8 December 2023. Related Party Transaction Certain of the directors of the Company have conditionally subscribed for, in aggregate, 2,187,588 Subscription Shares at the Issue Price, raising gross proceeds of approximately GBP0.20 million (C$0.34 million) for the Company, representing approximately 7.2 per cent of the New Common Shares (assuming a Fundraising of approximately GBP2.75 million (C$4.74 million) from the completed Placing and the Subscription participations confirmed to date). The number of New Common Shares conditionally subscribed for by each of the Directors, and their resulting shareholdings following the Admission of the Placing Shares and the Subscription Shares subscribed for to date, assuming no new issuance is made arising from the exercise of the Broker Option or any further subscriptions by employees, are set out below: Director Number of New Total Number % of issued share Common Shares of New Common capital as enlarged subscribed for Shares held on by the completed in the Subscription Admission Placing and Subscription to date(1) Carolyn Cross(2) 1,093,770 135,328,279 59.98% -------------------- Nicolas Loebel 218,754 2,852,088 1.26% -------------------- Craig Tooman 173,278 173,278 0.08% -------------------- Jean Duval 207,934 207,934 0.09% -------------------- Junaid Bajwa 190,610 317,735 0.14% -------------------- Michael Farrer 86,642 86,642 0.04% -------------------- Simon Sinclair 216,600 472,927 0.21% -------------------- 1 These figures are subject to change in the event of further new issuance under the Employee Subscription or as a result of the exercise of some or all of the Broker Option. 2 Existing beneficial holding includes 108,376109 shares held by Mrs Carolyn Cross, including via holdings in 100% owned companies, and 25,858,400 shares held by Mr Robert Cross, husband of Mrs Carolyn Cross. The subscriptions by the Participating Directors constitute a related party transaction for the purposes of Rule 13 of the AIM Rules by virtue of such persons being directors of the Company and therefore related parties (the "Transaction"). The director independent of the Participating Directors, being Hon. Jean Charest, considers, having consulted with the Company's nominated adviser, that the terms of the participation by the Participating Directors, are fair and reasonable insofar as the Company's shareholders are concerned. Admission, Settlement and Dealings Admission of the Placing Shares and Subscription Shares will take place on or before 8.00 a.m. on 8 December 2023 and dealings on AIM in the Placing Shares and the Subscription Shares (excluding any to be issued from the Employee Subscription) will commence at the same time. Admission is conditional upon, among other things, the Placing Agreement not having been terminated and becoming unconditional in all respects. The Placing Shares and Subscription Shares when issued, will be fully paid and will rank pari passu in all respects with the Existing Common Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of issue. Total Voting Rights Following admission of the Placing Shares and Subscription Shares (excluding any arising from the Broker Option or Employee Subscription), the Company's issued and fully paid share capital will consist of 225,617,679 Common Shares, all of which carry one voting right per share. The Company does not hold any Common Shares in treasury. Therefore, the total number of Common Shares and voting rights in the Company will be 225,617,679 after the admission of the Placing Shares and the Subscription Shares (excluding any from the Broker Option Employee Subscription) |
Posted at 05/12/2023 07:54 by z1co Not surprised at all that institutional investors want more at these very low prices ahead of the phase 3 trials in the US. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
